
Trevor G Hackman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2074309/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. Journal of Clinical Oncology, 2020, 38, 1050-1058.	1.6	219
2	Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clinical Cancer Research, 2019, 25, 4682-4690.	7.0	195
3	Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, 976-985.	0.8	163
4	Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2019, 37, 2661-2669.	1.6	130
5	Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncology, 2017, 72, 98-103.	1.5	119
6	Mature results of a prospective study of deintensified chemoradiotherapy for lowâ€risk human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. Cancer, 2018, 124, 2347-2354.	4.1	107
7	Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research, 2020, 26, 4260-4267.	7.0	35
8	Angiosarcoma of the Head and Neck. International Archives of Otorhinolaryngology, 2015, 19, 191-195.	0.8	31
9	Multimodal Analgesia Protocol after Head and Neck Surgery: Effect on Opioid Use and Pain Control. Otolaryngology - Head and Neck Surgery, 2019, 161, 424-430.	1.9	27
10	Cost-Effectiveness Analysis of Virtual Surgical Planning in Mandibular Reconstruction. Plastic and Reconstructive Surgery, 2019, 143, 1185-1194.	1.4	27
11	Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 646-653.	0.8	27
12	Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma. Cancer Cytopathology, 2015, 123, 531-539.	2.4	23
13	Transoral robotic surgery for upper airway pathology in the pediatric population. Laryngoscope, 2017, 127, 247-251.	2.0	22
14	RNA Oncoimmune Phenotyping of HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas by Nodal Status. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 967.	2.2	21
15	Malignant Peripheral Nerve Sheath Tumors of the Head and Neck: A Case Series and Literature Review. Case Reports in Otolaryngology, 2014, 2014, 1-6.	0.2	19
16	Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. Oral Oncology, 2018, 78, 108-113.	1.5	19
17	Inâ€office versus Operating Room Sialendoscopy: Comparison of Outcomes, Patient Time Burden, and Charge Analysis. Otolaryngology - Head and Neck Surgery, 2019, 160, 255-260.	1.9	17
18	Dosimetric feasibility of sparing the primary site for oropharyngeal squamous cell carcinoma after transoral laser microsurgery in patients with unilateral positive neck nodes. Practical Radiation Oncology, 2013, 3, 282-286.	2.1	16

TREVOR G HACKMAN

#	Article	IF	CITATIONS
19	Age and risk of recurrence in oral tongue squamous cell carcinoma: Systematic review. Head and Neck, 2020, 42, 3755-3768.	2.0	16
20	Socioeconomic Status Drives Racial Disparities in <scp>HPV</scp> â€negative Head and Neck Cancer Outcomes. Laryngoscope, 2021, 131, 1301-1309.	2.0	15
21	Patterns of local failure for sinonasal malignancies. Practical Radiation Oncology, 2013, 3, e113-e120.	2.1	14
22	Accuracy of Ultrasonography-Guided Fine-Needle Aspiration in Detecting Persistent Nodal Disease After Chemoradiotherapy. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 377.	2.2	14
23	Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with riskâ€adapted adjuvant therapy for squamous cell carcinoma of the head and neck. Cancer, 2018, 124, 2986-2992.	4.1	13
24	Academic Affiliation and Surgical Volume Predict Survival in Head and Neck Cancer Patients Receiving Surgery. Laryngoscope, 2021, 131, E479-E488.	2.0	13
25	Oncologic outcomes of human papillomavirus–associated oropharynx carcinoma treated with surgery alone: A 12â€institution study of 344 patients. Cancer, 2021, 127, 3092-3106.	4.1	13
26	Impact of Tumor Site and Adjuvant Radiotherapy on Survival of Patients with Adenoid Cystic Carcinoma: A SEER Database Analysis. Cancers, 2021, 13, 589.	3.7	12
27	Endoscopic Adipofascial Radial Forearm Flap Reconstruction of a Clival Defect. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e1109.	0.6	11
28	Endoscopic surgical management of vidian nerve schwannoma. Laryngoscope, 2011, 121, 241-244.	2.0	10
29	Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life. Oral Oncology, 2016, 58, 21-26.	1.5	10
30	Anatomic factors affecting the use of ultrasound to predict vocal fold motion: A pilot study. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2018, 39, 413-417.	1.3	10
31	Decline in circulating viral and human tumor markers after resection of head and neck carcinoma. Head and Neck, 2021, 43, 27-34.	2.0	10
32	Adult Alveolar Soft Part Sarcoma of the Head and Neck: A Report of Two Cases and Literature Review. Case Reports in Oncological Medicine, 2014, 2014, 1-5.	0.3	9
33	Association of Standardized Tracheostomy Care Protocol Implementation and Reinforcement With the Prevention of Life-Threatening Respiratory Events. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 527.	2.2	9
34	Genomic heterogeneity and copy number variant burden are associated with poor recurrenceâ€free survival and 11q loss in human papillomavirusâ€positive squamous cell carcinoma of the oropharynx. Cancer, 2021, 127, 2788-2800.	4.1	9
35	De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches. Practical Radiation Oncology, 2012, 2, 282-287.	2.1	8
36	Simultaneous Incidental Parathyroid Carcinoma and Intrathyroid Parathyroid Gland in Suspected Renal Failure Induced Hyperparathyroidism. The Surgery Journal, 2017, 03, e23-e24.	0.7	8

TREVOR G HACKMAN

#	Article	IF	CITATIONS
37	Chronic atypical first bite syndrome and primary squamous cell carcinoma of the parotid. Head and Neck, 2018, 40, E82-E86.	2.0	8
38	Socioeconomic status, access to care, risk factor patterns, and stage at diagnosis for head and neck cancer among black and white patients. Head and Neck, 2022, 44, 823-834.	2.0	8
39	Shoulder symptoms and quality of life impact of limited neck dissection after deâ€intensified chemoradiotherapy: Secondary analysis of two prospective trials. Head and Neck, 2019, 41, 1213-1219.	2.0	6
40	CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARÎ ³ inhibition. Cell Reports, 2021, 34, 108768.	6.4	6
41	Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma Journal of Clinical Oncology, 2016, 34, TPS6106-TPS6106.	1.6	6
42	Postoperative Analgesic Requirement and Pain Perceptions after Nonaerodigestive Head and Neck Surgery. Otolaryngology - Head and Neck Surgery, 2019, 161, 970-977.	1.9	5
43	Access to preventive care services and stage at diagnosis in head and neck cancer. Head and Neck, 2020, 42, 2841-2851.	2.0	5
44	Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck – Mature clinical and functional outcomes. Oral Oncology, 2020, 110, 104957.	1.5	5
45	Comprehensive Viral Genotyping Reveals Prognostic Viral Phylogenetic Groups in HPV16-Associated Squamous Cell Carcinoma of the Oropharynx. Molecular Cancer Research, 2022, 20, 1489-1501.	3.4	5
46	Preservation of swallowing function with de-intensified chemoradiation therapy for HPV-associated oropharyngeal squamous cell carcinoma. Advances in Radiation Oncology, 2018, 3, 356-365.	1.2	4
47	The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediateâ€risk HPVâ€negative HNSCC. Cancer Medicine, 2021, 10, 3231-3239.	2.8	4
48	Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma. Oral Oncology, 2021, 119, 105377.	1.5	3
49	Quantifying smoking exposure, genomic correlates, and related risk of treatment failure in <scp>p16</scp> + squamous cell carcinoma of the oropharynx. Laryngoscope Investigative Otolaryngology, 2021, 6, 1376-1382.	1.5	3
50	Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 200-205.	1.3	2
51	Phase I study of durvalumab and tremelimumab together with radiotherapy for the adjuvant treatment of intermediate-risk head and neck squamous cell carcinoma Journal of Clinical Oncology, 2019, 37, TPS73-TPS73.	1.6	1
52	Evaluation of a 3Dâ€Printed Transoral Robotic Surgery Simulator Utilizing Artificial Tissue. Laryngoscope, 2021, , .	2.0	1
53	Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma. Oral Oncology, 2022, 127, 105807.	1.5	1
54	Radiographic muscle invasion not a recurrence predictor in HPV â€associated oropharyngeal squamous cell carcinoma. Laryngoscope, 2019, 129, 871-876.	2.0	0

TREVOR G HACKMAN

#	Article	IF	CITATIONS
55	Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography. Nuclear Medicine Communications, 2020, 41, 228-234.	1.1	Ο
56	Number of nodal metastases associated with overall survival in HPV-negative head and neck cancer Journal of Clinical Oncology, 2018, 36, 6062-6062.	1.6	0
57	The addition of chemotherapy to adjuvant therapy in patients with intermediate risk HNSCC may cause harm Journal of Clinical Oncology, 2018, 36, e18057-e18057.	1.6	ο